

Editorial

Current Oncology: A Multidisciplinary Medium for Clinical Oncology

Sharlene Gill

Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 4E6, Canada; sgill@bccancer.bc.ca

Received: 25 November 2020; Accepted: 25 November 2020; Published: 28 November 2020



In recent years, the field of oncology has witnessed the unprecedented pace of genomics discovery, knowledge translation, and clinical research validation, which has led to novel systemic and locoregional therapeutics, an evolving role of immunotherapy, and a broader application of precision oncology. At the same time, we are gaining a greater appreciation for adaptive trial designs, real-world evidence, and patient-reported outcomes to better inform the optimal utilization of new therapies which offer the greatest benefit to our patients for the greatest value to society.

Within this era of exciting developments, I am delighted to assume the role of Editor-in-Chief for *Current Oncology* [1]—a scientific, peer-reviewed open access journal established in 1994 in Canada, and now published bi-monthly by MDPI (Basel, Switzerland). This journal provides a platform to disseminate high-quality, original clinical research, expert reviews, and periodic Special Issues—with the clinical oncologist and healthcare provider audience in mind. *Current Oncology* is committed to being recognized as an outstanding clinical oncology journal with rigorous peer review and an efficient publication process.

On behalf of the Editorial Board and team, I welcome you to *Current Oncology* and encourage you to submit your original research works to the journal. We look forward to your contributions and continued engagement.

Conflicts of Interest: The author declares no conflict of interest.

Reference

1. *Current Oncology* New Homepage. Available online: <https://www.mdpi.com/journal/curroncol> (accessed on 24 November 2020).

Short Biography of Author



Dr. Gill is Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer, Vancouver. She received her BSc in Pharmacy and MD from the University of British Columbia in 1996, followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in GI Oncology at the Mayo Clinic (Rochester, MN) and Master of Public Health at the Harvard School of Public Health. In 2017, she completed her MBA at the Kenan-Flagler School of Business, University of North Carolina. She is actively engaged in education and research, with over 100 peer-reviewed publications and book chapters to her credit. Dr. Gill currently serves as Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee, and is President-Elect of the Canadian Association of Medical Oncologists.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).